Multicenter observational study on HER2 Status in HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab KSCC1604 (HER2 retry study)

Not Applicable

• Conditions: Gastric Cancer

• Registration Number: JPRN-UMIN000024492
• Lead Sponsor: Kyushu Study group of Clinical Cancer

Brief Summary

1.ASCO 2018(2018/6/1~5 CHICAGO,ILLINOIS in USA) Multicenter observational study on re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604) Tomomi Kashiwada 2.The 56th Annual Meeting of JSCO(2018/10/18~20 Yokohama) Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604) Takaaki Arigami 3.European Journal of Cancer Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604) European Journal Of Cancer Hiroshi Saeki

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-10-21
• Study Completion: 2018-08-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

Patients who are regarded as unsuitable for this study by the investigators.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Rate of HER2 positivity after resistance to trastuzumab treatment

Secondary Outcome Measures

Name	Time	Method
Amplification of EGFR and c-met gene, PIK3CA gene mutation as biomarkers that associate with resistance to trastuzumab.